Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kolon Life Science Inc.

http://www.kolonls.co.kr/eng

Latest From Kolon Life Science Inc.

Pink Sheet Podcast: Gene Therapy Withdrawal, Gene Therapy Approval, DTC Price Disclosure Rule

Our discussion of South Korea pulling approval of a gene therapy, the US FDA's approval of Zolgensma, and an industry debate over challenging the DTC ad price disclosure requirement.
Gene Therapy Advertising, Marketing & Sales

Invossa Fallout: Call For Review Of All Korea-Approved Cell Therapies

Although the big decision has been made for Invossa in Korea, things have not settled down and there have been calls for re-examination of all approved cell therapies, the recall of R&D grants provided to Kolon and expansion of a probe into the company’s leadership and government officials.

South Korea Gene Therapy

Invossa Approval Revoked As Korea Confirms False Data Submission

In a worst case scenario for the country’s first approved gene therapy, South Korea has cancelled the global-first approval of Kolon Life’s Invossa and asked prosecutors to press criminal charges against the company, which it concluded submitted false data to support approval. The major blow to the company comes as it is already facing lawsuits from patients and investors, and has prompted a broader regulatory overhaul for novel biologic therapies.

Gene Therapy South Korea

Korea Pledges Broad Innovation, Policy Support As It Eyes Global Stage

After selecting the bio-health sector as one of three major industries to nurture, South Korea unveils new strategy to triple the industry’s global market share and improve regulations in line with global standards, with a focus on the pharma and medical device sectors. While industry supports the move, some uncertainties could slow the government’s efforts.

South Korea Policy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Kolon Life Science Inc.
  • Senior Management
  • Woo-Sok Lee, CEO
  • Contact Info
  • Kolon Life Science Inc.
    Phone: 02 3677-4150
    Fl. 7, Kolon Tower annex, Kolon 13
    Gwachun-si,
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register